logo
Plus   Neg
Share
Email

Accenture Raises FY19 Outlook; Boosts Semi-annual Dividend 10% - Quick Facts

While reporting financial results for the second quarter on Thursday, Accenture Plc (ACN) raised its business outlook for the full-year 2019 and provided revenue guidance for the third quarter.

For fiscal 2019, the company now expects earnings in a range of $7.18 to $7.32 per share on revenue growth of 6.5 to 8.5 percent in local currency.

Previously, the company projected earnings in the range of $7.01 to $7.25 per share on revenue growth of 6 to 8 percent in local currency.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $7.23 per share on revenue growth of 8.4 percent to $42.9 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, Accenture expects revenues to be in the range of $10.80 billion to $11.10 billion, 5.5 percent to 8.5 percent growth in local currency, reflecting the company's assumption of a negative 4.5 percent foreign-exchange impact compared with the third quarter of fiscal 2018.

The Street is looking for revenue growth of 7.1 percent to $11.05 billion for the quarter.

Accenture also declared a 10 percent higher semi-annual cash dividend of $1.46 per share, payable on May 15, 2019 to shareholders of record at the close of business on April 11, 2019.

As previously disclosed, the company plans to begin paying dividends on a quarterly basis in the first quarter of fiscal 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products. Hundreds of Facebook employees staged a "virtual walkout" on Monday to protest the company's decision not to act on recent controversial posts by President Donald Trump on the social media platform. The employees criticized Facebook chief executive Mark Zuckerberg's decision to not moderate a post from Trump last Thursday.
Follow RTT